🇺🇸 FDA
Pipeline program

Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector

C12-48

Phase 2 small_molecule active

Quick answer

Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector for Recessive dystrophic epidermolysis bullosa (RDEB) is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
The George Institute
Indication
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials